Diagnostic accuracy of serum hyaluronic acid, FIBROSpect II, and YKL-40 for discriminating fibrosis stages in chronic hepatitis C

American Journal of Gastroenterology

Volumn 103, Issue 4, 2008, Pages 928-936

  Mehta, Preeti ^a   Ploutz Snyder, Robert ^a   Nandi, Jyotirmoy ^a   Rawlins, Sekou R ^a   Sanderson, Schuyler O ^b   Levine, Robert A ^a  

^a State University of New York Upstate Medical University: College of Medicine   (United States)

^b Mayo Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA 2 MACROGLOBULIN; BIOLOGICAL MARKER; GLYCOPROTEIN GP 39; HYALURONIC ACID; TISSUE INHIBITOR OF METALLOPROTEINASE 1;

ADULT; AREA UNDER THE CURVE; ARTICLE; CORRELATION COEFFICIENT; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; FEMALE; HEPATITIS C; HUMAN; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PRESSURE VOLUME CURVE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SCORING SYSTEM;

ADULT; AGED; BIOLOGICAL MARKERS; BIOPSY; EXTRACELLULAR MATRIX PROTEINS; FEMALE; GLYCOPROTEINS; HEPATITIS C, CHRONIC; HUMANS; HYALURONIC ACID; LIVER CIRRHOSIS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; ROC CURVE; SENSITIVITY AND SPECIFICITY;

EID: 41849135398     PISSN: 00029270     EISSN: 15720241     Source Type: Journal    
DOI: 10.1111/j.1572-0241.2007.01761.x     Document Type: Article

References (49)

1. Bedossa P, Dargère D, Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003 38 : 1449 57.
2. Regev A, Berho M, Jeffers LJ, et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002 97 : 2614 8.
3. Guido M, Rugge M. Liver biopsy sampling in chronic viral hepatitis. Semin Liver Dis 2004 24 : 89 97.
4. Rockey DC, Bissell DM. Noninvasive measures of liver fibrosis. Hepatology 2006 43 : S113 20.
5. Brady CW, McHutchison JG, Patel K. Fibrosis markers in hepatitis C. Curr Hepat Rep 2006 5 : 12 9.
6. Kelleher TB, Afdhal N. Noninvasive assessment of liver fibrosis. Clin Liver Dis 2005 9 : 667 83.
7. Patel K, Gordon SC, Jacobson I, et al. Evaluation of a panel of noninvasive serum markers to differentiate mild from moderate-to-advanced liver fibrosis in chronic hepatitis C patients. J Hepatol 2004 41 : 935 42.
8. Lazzarini AL, Levine RA, Ploutz-Snyder RJ, et al. Advances in digital quantification technique enhance discrimination between mild and advanced liver fibrosis in chronic hepatitis C. Liver Int 2005 25 : 1 8.
9. Levine RA, Sanderson SO, Ploutz-Snyder R, et al. Lack of fibrosis progression in untreated Irish women with chronic hepatitis C contracted from immunoglobulin anti-D. Clin Gastroenterol Hepatol 2006 4 : 1271 7.
10. Guechot J, Poupon RE, Giral P, et al. Relationship between procollagen III aminoterminal propeptide and hyaluronan serum levels and histological fibrosis in primary biliary cirrhosis and chronic viral hepatitis C. J Hepatol 1994 20 : 388 93.
11. Nyberg A, Lindqvist J, Engstrom-Laurent A. Serum hyaluronan and aminoterminal propeptide of type III procollagen in primary biliary cirrhosis: Relation to clinical symptoms, liver histopathology and outcome. J Intern Med 1992 231 : 485 91.
12. Murawaki Y, Ikuta Y, Nishimura Y, et al. Serum markers for connective tissue turnover in patients with chronic hepatitis B and chronic hepatitis C: A comparative analysis. J Hepatol 1995 23 : 145 52.
13. Yamada M, Fukuda Y, Nakano I, et al. Serum hyaluronan as a marker of liver fibrosis in hemophiliacs with hepatitis C virus-associated chronic liver disease. Acta Haematol 1998 99 : 212 6.
14. Parés A, Deulofeu R, Giménez A, et al. Serum hyaluronate reflects hepatic fibrogenesis in alcoholic liver disease and is useful as a marker of fibrosis. Hepatology 1996 24 : 1399 403.
15. Lydatakis H, Hager I-P, Kostadelou E, et al. Noninvasive markers to predict the liver fibrosis in non-alcoholic fatty liver disease. Liver Int 2006 26 : 864 71.
16. Oberti F, Valsesia E, Pilette C, et al. Liver, pancreas, and biliary tract. Noninvasive diagnosis of hepatic fibrosis or cirrhosis. Gastroenterology 1997 113 : 1609 16.
17. Guéchot J, Laudat A, Loria A, et al. Diagnostic accuracy of hyaluronan and type III procollagen amino-terminal peptide serum assays as markers of liver fibrosis in chronic viral hepatitis C evaluated by ROC curve analysis. Clin Chem 1996 42 : 558 63.
18. Murawaki Y, Ikuta Y, Koda M, et al. Clinical significance of serum hyaluronan in patients with chronic viral liver disease. J Gastroenterol Hepatol 1996 11 : 459 65.
19. Halfon P, Bourlière M, Pénaranda G, et al. Accuracy of hyaluronic acid level for predicting liver fibrosis stages in patients with hepatitis C virus. Compar Hepatol 2005 4 : 6.
20. Wong VS, Hughes V, Trull A, et al. Serum hyaluronic acid is a useful marker of liver fibrosis in chronic hepatitis C virus infection. J Viral Hepatitis 1998 5 : 187 92.
21. Ninomiya T, Yoon S, Hayashi Y, et al. Clinical significance of serum hyaluronic acid as a fibrosis marker in chronic hepatitis C patients treated with interferon-alpha: Histological evaluation by a modified histology action by index scoring systems. J Gastroenterol Hepatol 1998 13 : 68 74.
22. Parise ER, Oliveira AC, Figueiredo-Mendes C, et al. Noninvasive serum markers in the diagnosis of structural liver damage in chronic hepatitis C virus infection. Liver Int 2006 26 : 1095 9.
23. McHutchison JG, Blatt LM, de Medina M, et al. Measurement of serum hyaluronic acid in patients with chronic hepatitis C and its relationship to liver histology. Consensus Interferon Study Group. J Gastroenterol Hepatol 2000 15 : 945 51.
24. Rosenberg WMC, Voelker M, Thiel R, et al. Clinical-liver, pancreas, and biliary tract. Serum markers detect the presence of liver fibrosis: A cohort study. Gastroenterology 2004 127 : 1704 13.
25. Guéchot J, Loria A, Serfaty L, et al. Serum hyaluronan as a marker of liver fibrosis in chronic viral hepatitis C: Effect of α-interferon therapy. J Hepatol 1995 22 : 22 6.
26. Yamada M, Fukuda Y, Koyama Y, et al. Serum hyaluronic acid reflects the effect of interferon treatment on hepatic fibrosis in patients with chronic hepatitis C. J Gastroenterol Hepatol 1996 11 : 646 51.
27. Leroy V, De Traversay C, Barnoud R, et al. Changes in histological lesions and serum fibrogenesis markers in chronic hepatitis C patients non-responders to interferon alpha. J Hepatol 2001 35 : 120 6.
28. Patel K, Lajoie A, Heaton S, et al. Clinical use of hyaluronic acid as a predictor of fibrosis change in hepatitis C. J Gastroenterol Hepatol 2003 18 : 253 7.
29. Trocme C, Leroy V, Sturm N, et al. Longitudinal evaluation of a fibrosis index combining MMP-1 and PIIINP compared with MMP-9, TIMP-1 and hyaluronic acid in patients with chronic hepatitis C treated by interferon-alpha and ribavirin. J Viral Hepatol 2006 13 : 643 51.
30. Saitou Y, Shiraki K, Yamanaka Y, et al. Noninvasive estimation of liver fibrosis and response to interferon therapy by a serum fibrogenesis marker, YKL-40, in patients with HCV-associated liver disease. World J Gastroenterol 2005 11 : 476 81.
31. Engstrom-Laurent A, Hallgren R. Circulating hyaluronate in rheumatoid arthritis: Relationship to inflammatory activity and the effect of corticosteroid therapy. Ann Rheum Dis 1985 44 : 83 8.
32. Engstrom-Laurent A, Feltelius N, Hallgren R, et al. Raised serum hyaluronate levels in scleroderma: An effect of growth factor induced activation of connective tissue cells? Ann Rheum Dis 1985 44 : 614 20.
33. Lundin A, Engstrom-Laurent A, Hallgren R, et al. Circulating hyaluronate in psoriasis. Br J Dermatol 1985 112 : 663 71.
34. Berg S, Brodin B, Hesselvik F, et al. Elevated levels of plasma hyaluronan in septicaemia. Scand J Clin Lab Invest 1988 48 : 727 32.
35. Laurent TC, Lilja K, Brunnberg L, et al. Urinary excretion of hyaluronan in man. Scand J Clin Lab Invest 1987 47 : 793 9.
36. Hallgren R, Engstrom-Laurent A, Nisbeth U. Circulating hyaluronate. A potential marker of altered metabolism of the connective tissue in uremia. Nephron 1987 46 : 150 4.
37. Fraser JR, Gibson PR. Mechanisms by which food intake elevates circulating levels of hyaluronan in humans. J Intern Med 2005 258 : 460 6.
38. Christensen C, Bruden D, Livingston S, et al. Diagnostic accuracy of a fibrosis serum panel (FIBROSpect II) compared with Knodell and Ishak liver biopsy scores in chronic hepatitis C patients. J Viral Hepatitis 2006 13 : 652 8.
39. Jeffers LJ, Cortes RA, Bejarano PA, et al. Prospective evaluation of FIBROSpect II for fibrosis detection in hepatitis C and B patients undergoing laparoscopic biopsy. Gastroenterol Hepatol 2007 3 : 367 76.
40. Zaman A, Rosen HR, Ingram K, et al. Assessment of FIBROSpect II to detect hepatic fibrosis in chronic hepatitis C patients. Am J Med 2007 120 : e9 14.
41. Lichtinghagen R, Huegel O, Seifert T, et al. Expression of matrix metalloproteinase-2 and -9 and their inhibitors in peripheral blood cells of patients with chronic hepatitis C. Clin Chem 2000 46 : 183 92.
42. Lichtinghagen R, Bahr MJ. Noninvasive diagnosis of fibrosis in chronic liver disease. Expert Rev Mol Diag 2004 4 : 715 26.
43. Naveau S, Poynard T, Benattar C, et al. Alpha-2-macroglobulin and hepatic fibrosis: Diagnostic interest. Dig Dis Sci 1994 39 : 2426 32.
44. Borth F. Alpha 2-macroglobulin. A multifunctional binding and targeting protein with possible roles in immunity and autoimmunity. Ann N Y Acad Sci 1994 737 : 267 72.
45. Johansen JS, Christoffersen P, Møller S, et al. Serum YKL-40 is increased in patients with hepatic fibrosis. J Hepatol 2000 32 : 911 20.
46. Johansen JS, Møller S, Price PA, et al. Plasma YKL-40: A new potential marker of fibrosis in patients with alcoholic cirrhosis? Scand J Gastroenterol 1997 32 : 582 90.
47. Tran A, Benzaken S, Saint-Paul M-C, et al. Chondrex (YKL-40), a potential new serum fibrosis marker in patients with alcoholic liver disease. Eur J Gastroenterol Hepatol 2000 12 : 989 93.
48. Kamal SM, Turner B, He Q, et al. Progression of fibrosis in hepatitis C with and without schistosomiasis: Correlation with serum markers of fibrosis. Hepatology 2006 43 : 771 9.
49. Parkes J, Guha IN, Roderick P, et al. Performance of serum marker panels for liver fibrosis in chronic hepatitis C. J Hepatol 2006 44 : 462 74.